GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform
Executive Summary
Generic drug user fees should only be considered in the context of changes to the Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA during a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.
You may also be interested in...
CBER User Fee Standards May Need To Differ From CDER's, Director Zoon Says
The Center for Biologics Evaluation & Research may need a different set of user fee review parameters than the drug center, CBER Director Kathryn Zoon, PhD, suggested during a Dec. 7 FDA public meeting on the Prescription Drug User Fee Act
CBER User Fee Standards May Need To Differ From CDER's, Director Zoon Says
The Center for Biologics Evaluation & Research may need a different set of user fee review parameters than the drug center, CBER Director Kathryn Zoon, PhD, suggested during a Dec. 7 FDA public meeting on the Prescription Drug User Fee Act
NAPM/GhPA Merger Likely Ends Generic User Fees Push In 107th
The merger agreement between the National Association of Pharmaceutical Manufacturers and the Generic Pharmaceutical Association likely means that generic drug user fees will not be a focal point of the PDUFA reauthorization process.